EXACT Therapeutics’ Phase 2 trial to be presented at the 2025 AACR Special Conference
EXACT Therapeutics’ Phase 2 trial to be presented at the 2025 AACR Special Conference
EXACT Therapeutics’ Phase 2 trial in pancreatic cancer patients to be presented at the 2025 AACR Special Conference on the Advances in Pancreatic Cancer Research
Oslo, Norway, 18 September 2025. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce that a poster on the ongoing Phase 2 ENACT trial in locally advanced pancreatic cancer patients (NCT06850623) will be presented at the upcoming 2025 AACR Special Conference on the Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions, which takes place during 28 September – 1 October, 2025, in Boston, Massachusetts.
The poster will be presented on the 29 September.
• Title: A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer
• Poster #: A068
• In collaboration with HonorHealth Research Institute, Scottsdale, AZ, United States
The poster will be made available on the Company’s website.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: [email protected]